Toyoma’s Rheumatoid Arthritis Drug T-5224 Enters Phase II
This article was originally published in PharmAsia News
Toyoma Chemical's rheumatoid arthritis drug T-5224 enters Phase II clinical trials. The low-polymer compound concluded Phase I trials in June 2006; results indicated the compound may prevent breakdown in joints and bones. Toyama signed a research, development and marketing license with Hoffman La Roche Ltd. (Click for more - Japanese language)
You may also be interested in...
Designed to decrease venous leak from the corpora cavernosa, Giddy makes its Eddie device in oblong shape that opens at one point into two S-forms. Elastic bands are placed around the S-forms to pull the shape together at variable tensions.
Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.